The treatment gap in mental health care
Robert Kohn,1 Shekhar Saxena,2 Itzhak Levav,3 & Benedetto Saraceno2

Abstract Mental disorders are highly prevalent and cause considerable suffering and disease burden. To compound this public health problem, many individuals with psychiatric disorders remain untreated although effective treatments exist. We examine the extent of this treatment gap. We reviewed community-based psychiatric epidemiology studies that used standardized diagnostic instruments and included data on the percentage of individuals receiving care for schizophrenia and other non-affective psychotic disorders, major depression, dysthymia, bipolar disorder, generalized anxiety disorder (GAD), panic disorder, obsessive–compulsive disorder (OCD), and alcohol abuse or dependence. The median rates of untreated cases of these disorders were calculated across the studies. Examples of the estimation of the treatment gap for WHO regions are also presented. Thirty-seven studies had information on service utilization. The median treatment gap for schizophrenia, including other non-affective psychosis, was 32.2%. For other disorders the gap was: depression, 56.3%; dysthymia, 56.0%; bipolar disorder, 50.2%; panic disorder, 55.9%; GAD, 57.5%; and OCD, 57.3%. Alcohol abuse and dependence had the widest treatment gap at 78.1%. The treatment gap for mental disorders is universally large, though it varies across regions. It is likely that the gap reported here is an underestimate due to the unavailability of community-based data from developing countries where services are scarcer. To address this major public health challenge, WHO has adopted in 2002 a global action programme that has been endorsed by the Member States.

Keywords Mental health services/utilization; Health services accessibility; Schizophrenia/therapy; Anxiety disorders/therapy; Mood disorders/therapy; Compulsive personality disorder/therapy; Alcoholism/therapy; Epidemiologic studies; Cost of Illness; Americas; Europe (source: MeSH, NLM).

Mots clés Service santé mentale/utilisation; Accès aux services de santé; Schizophrénie/thérapie; Troubles de l’anxiété/thérapie; Troubles de l’humeur/thérapie; Personnalité compulsive/thérapie; Alcoolisme/thérapie; Études épidémiologiques; Coût de l’Illégalité; Amérique; Europe (source: MeSH, INSERM).

Palabras clave Servicios de salud mental/utilización; Accesibilidad a los servicios de salud; Esquizofrenia/terapia; Trastornos de ansiedad/terapia; Trastornos del humor/terapia; Trastorno de personalidad compulsiva/terapia; Alcoholismo/terapia; Estudios epidemiológicos; Costo de la enfermedad; Americas; Europa (fuente: DeCS, BIREME).

Introduction The care of people with mental and brain disorders is a growing public health concern. These disorders are highly prevalent and exact a high emotional toll on individuals, families, and society. Worldwide, community-based epidemiological studies have estimated rates of lifetime prevalence of mental disorders among adults ranging from 12.2% to 48.6% and 12-month prevalence rates ranging from 8.4% to 29.1% (1). These rates do not include neurological conditions affecting the brain (1). WHO (2) has estimated that approximately 450 million individuals worldwide suffer from neuropsychiatric disorders in their lifetime.

Mental disorders are not only highly prevalent medical conditions but they are also highly disabling. Measured by years lived with disability and by premature death in disability-adjusted life years (DALYs), psychiatric and neurological conditions accounted for over 13% of the global disease burden in the year 2001 (3). When compared with 1990, the contribution of neuropsychiatric disorders is expected to increase to almost 15% by the year 2020 (4). Among individuals age 15–44, unipolar depression is the second leading contributor of DALYs, with alcohol-related disorders, schizophrenia, and bipolar disorder among the top 10 disorders. Approximately 33% of all years lived with disability (YLD) are imputed to neuropsychiatric conditions. Of the 10 leading causes of YLD in the world among individuals of all ages, four are psychiatric conditions, with unipolar depression being the leading cause (2). Among individuals between the ages of 15 and 44, panic disorder, drug use disorders, and obsessive–compulsive disorder (OCD) were included in the top 20 disorders.

1 Brown University Department of Psychiatry and Human Behavior, Providence, RI, USA. Correspondence should be sent to Dr Kohn at Butler Hospital, 345 Blackstone Blvd, Providence, RI, USA, (email: Robert_Kohn@brown.edu).
2 World Health Organization, Department of Mental Health and Substance Dependence, Geneva, Switzerland.
3 Ministry of Health, Jerusalem, Israel.

Ref No. 03-005736
(Submitted: 22 June 2003 – Final revised version received: 20 November 2003 – Accepted: 21 November 2003)
In part, the excess disability due to mental disorders is a result of their early age of onset (1). The magnitude of this burden also results from the fact that only a minority of individuals with these disorders ever receive treatment in the specialized mental health care system or in the general health care system (5); initial treatment is frequently delayed for many years (6). Numerous reasons have been imputed. These include: failing to seek help because the problem is not acknowledged, perceiving that treatment is not effective, believing that the problem will go away by itself, and desiring to deal with the problem without outside help (7, 8). In addition a lack of knowledge about mental disorders and stigma remain major barriers to care (9, 10). Factors that are direct barriers to care also preclude treatment, including financial considerations (11), issues of accessibility, as well as limited availability or lack of availability of services in many countries or for some populations (12).

If disability is to be reduced, a bridging of the “treatment gap” must occur. The treatment gap represents the absolute difference between the true prevalence of a disorder and the treated proportion of individuals affected by the disorder. Alternatively, the treatment gap may be expressed as the percentage of individuals who require care but do not receive treatment. Estimating the treatment gap in a population depends on the prevalence period of the disorder, the time frame of the examination of service utilization, and the demographic representativeness of the study sample with reference to the target population. The objective of this report is to examine the extent of the treatment gap for selected mental disorders.

Methods

To examine the worldwide extent of the treatment gap the following disorders were selected: schizophrenia and non-affective psychosis, major depressive disorder, dysthymia, bipolar disorder, OCD, panic disorder, generalized anxiety disorder (GAD), and alcohol abuse and dependence. The literature review was limited to community-based epidemiological surveys of adults age 15 and older that had been published since 1980 or provided by investigators or agencies. The literature search was conducted using the search engines of medical journals, Medline and LILACS (a database of Latin American and Caribbean literature), and using key words that included the terms “psychiatric epidemiology,” “prevalence” and the name of a specific disorder, and the names of commonly used diagnostic instruments. The references of book chapters and review articles on psychiatric epidemiology or service utilization were examined. We also searched abstracts from proceedings of meetings of the World Psychiatric Association section on epidemiology and the annual meeting of the American Psychiatric Association.

The studies considered used standardized data collection instruments that generated a diagnosis linked to accepted classification systems. Surveys relying on diagnostic instruments designed specifically for use only in elderly populations were not included. Data on service utilization were obtained from community-based epidemiological studies of psychiatric disorders regardless of prevalence periods. Service utilization was defined as seeking assistance from any medical or professional service provider, specialized or not, public or private. By definition, traditional healers and non-professional providers were excluded. The category of service utilization included both somatic and psychotherapeutic treatment; however, most studies did not report utilization by treatment modality, thus limiting the analysis to overall utilization. The treatment gap from each of the available studies was determined for each specific disorder.

The median and average rates of service utilization across the studies were calculated for each disorder. Using the median rate prevents outliers from having an undue influence. Adequate data were not available for all WHO regions, but examples of regional treatment gap rates were calculated. Regional treatment gap (G) calculations take into account the service utilization rate (S), the prevalence rate (R), and the population size (P) of each of the countries:

\[ G = \sum \left( \frac{1-S}{R} \right) \frac{P}{\sum R} \]

We estimated the population in each country of individuals age 15 and older. The latest census data by age distribution were obtained from the United Nations demographic yearbook (13). Since the last census year varied from country to country, the estimates prepared by WHO for the year 1999 were used (14). These estimates provided data only on an individual Member country’s total population. To estimate the proportion of individuals aged 15 and older, data from the last census was applied to the 1999 total population estimate to obtain an approximation of each country’s population as well as of regional populations.

Results

A description of the 37 studies with data on service utilization is included in Appendix 1. The references are available in Appendix 2 (Appendix 1 and Appendix 2, web version only, available at: http://www.who.int/bulletin). The treatment gap is shown as percentage and the median and average treatment gap for each disorder is shown in Table 1. Where available, the rates of use of specialized mental health services are presented.

The median untreated rate, or treatment gap, for schizophrenia including other non-affective psychoses was 32.2%. For other disorders the gap was: major depression, 56.3%; dysthymia, 56.0%; bipolar disorder, 50.2%; panic disorder, 55.9%; GAD, 57.5%; and OCD, 59.5%. Alcohol abuse and dependence had the largest treatment gap at 78.1%. The treatment gap varied widely between countries. As an illustration, for schizophrenia the gap among young adult Jews in Israel was only 5.9%, while the rate in New Zealand in a population of 21-year-olds was 61.5%. The treatment gap in Italy was 15.9% for major depression, while studies in the United Kingdom gave an estimate of 83.9%. The treatment gap for alcohol abuse and dependence was high across all studies: Jewish-Israeli young adults had the lowest gap (49.4%) but in Mexico City among the general adult population few were in treatment (96.0%).

Service-related information from psychiatric epidemiological studies for many regions of the world was not available, so regional estimates of the treatment gap were not possible. As a result, examples of the treatment gap for major depression are presented for the Americas and the European Regions of WHO, since there is a good representation of studies across the countries in these two regions. The 12-month prevalence, or if not available, the current prevalence, were applied. When more than one study was available for a country, the most representative ones were used (those that referred to the entire sample studied). For the United States, the Epidemiological Catchment Area (ECA) and National Comorbidity Survey (NCS) prevalence and service utilization rates were averaged, as
### Table 1: Percentage difference between number of people needing treatment for mental illness and number of people receiving treatment (treatment gap) found using studies of service utilization rates for selected psychiatric disorders in community-based surveys

<table>
<thead>
<tr>
<th>Place or name of study</th>
<th>Prevalence period for help-seeking (months)</th>
<th>Mental disorder</th>
<th>Prevalence of study</th>
<th>Prevalence of study</th>
<th>Prevalence of study</th>
<th>Prevalence of study</th>
<th>Prevalence of study</th>
<th>Prevalence of study</th>
<th>Prevalence of study</th>
<th>Prevalence of study</th>
<th>Prevalence of study</th>
<th>Prevalence of study</th>
<th>Prevalence of study</th>
<th>Prevalence of study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia (1–3)</td>
<td>12</td>
<td>Schizophrenia</td>
<td>12</td>
<td>45.0</td>
<td>72.0</td>
<td>53.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>São Paulo, Brazil (4)</td>
<td>1</td>
<td>Major depression</td>
<td>12</td>
<td>49.4</td>
<td>46.0</td>
<td>47.8</td>
<td>41.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Edmonton, Canada (5, 6)</td>
<td>12</td>
<td>Dysthymia</td>
<td>12</td>
<td>43.8</td>
<td>64.0</td>
<td>84.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ontario, Canada (7–9)</td>
<td>12</td>
<td>Bipolar disorder</td>
<td>12</td>
<td>39.8</td>
<td>47.0</td>
<td>40.0</td>
<td>78.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chile (10)</td>
<td>6</td>
<td>Generalized anxiety disorder</td>
<td>12</td>
<td>50.2</td>
<td>44.2</td>
<td>27.6</td>
<td>83.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 areas, China (11)</td>
<td>Lifetime</td>
<td>Obsessive-compulsive disorder</td>
<td>Lifetime</td>
<td>22.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14 towns, China (12)</td>
<td>Lifetime</td>
<td>Alcohol abuse or dependence</td>
<td>Lifetime</td>
<td>43.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Czech Republic (13, 14)</td>
<td>Lifetime</td>
<td>Schizophrenia</td>
<td>Lifetime</td>
<td>54.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mini survey, Finland (15, 16)</td>
<td>1</td>
<td>Major depression</td>
<td>Lifetime</td>
<td>14.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FINHCS, Finland (17, 18)</td>
<td>12</td>
<td>Bipolar disorder</td>
<td>Lifetime</td>
<td>73.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paris, France (19)</td>
<td>Lifetime</td>
<td>Generalized anxiety disorder</td>
<td>Lifetime</td>
<td>26.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Munich, Germany (20)</td>
<td>Lifetime</td>
<td>Obsessive-compulsive disorder</td>
<td>Lifetime</td>
<td>60.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Madras, India (21)</td>
<td>Lifetime</td>
<td>Alcohol abuse or dependence</td>
<td>Lifetime</td>
<td>54.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Israel (22)</td>
<td>Lifetime</td>
<td>Schizophrenia</td>
<td>Lifetime</td>
<td>28.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Florence, Italy (23, 24)</td>
<td>12</td>
<td>Major depression</td>
<td>Lifetime</td>
<td>9.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lebanon (25)</td>
<td>Lifetime</td>
<td>Bipolar disorder</td>
<td>Lifetime</td>
<td>70.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mexico City, Mexico (26–28)</td>
<td>Lifetime</td>
<td>Generalized anxiety disorder</td>
<td>Lifetime</td>
<td>73.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rural areas, Mexico (29)</td>
<td>Lifetime</td>
<td>Obsessive-compulsive disorder</td>
<td>Lifetime</td>
<td>66.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LASA, Netherlands (30)</td>
<td>6</td>
<td>Alcohol abuse or dependence</td>
<td>Lifetime</td>
<td>21.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NEMESIS, Netherlands (31, 32)</td>
<td>12</td>
<td>Schizophrenia</td>
<td>Lifetime</td>
<td>53.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Christchurch, New Zealand (33, 34)</td>
<td>12</td>
<td>Major depression</td>
<td>Lifetime</td>
<td>60.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dunedin, New Zealand (35)</td>
<td>12</td>
<td>Bipolar disorder</td>
<td>Lifetime</td>
<td>61.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norway (36)</td>
<td>Lifetime</td>
<td>Generalized anxiety disorder</td>
<td>Lifetime</td>
<td>30.0</td>
<td></td>
<td>33.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zurich, Switzerland (37)</td>
<td>Lifetime</td>
<td>Obsessive-compulsive disorder</td>
<td>Lifetime</td>
<td>51.0</td>
<td></td>
<td>38.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Table 1, cont.

<table>
<thead>
<tr>
<th>Place or name of study</th>
<th>Prevalence period for help-seeking (months)</th>
<th>Mental disorder</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Schizophrenia and non-affective psychoses</td>
</tr>
<tr>
<td>Taiwan, China</td>
<td>Lifetime</td>
<td>79.6</td>
</tr>
<tr>
<td>Turkey (40)</td>
<td>12</td>
<td>62.6</td>
</tr>
<tr>
<td>ONS, United Kingdomb, c</td>
<td>12</td>
<td>56.0</td>
</tr>
<tr>
<td>OPCS, United Kingdomh</td>
<td>12</td>
<td>56.0</td>
</tr>
<tr>
<td>Sleep Eval, United Kingdom (44)</td>
<td>Current</td>
<td>83.9</td>
</tr>
<tr>
<td>ECA, USA (45, 46)</td>
<td>12</td>
<td>57.9</td>
</tr>
<tr>
<td>Mexican-Americans in CA, USAa, c</td>
<td>12</td>
<td>75.2</td>
</tr>
<tr>
<td>NCS, USA (49, 50)</td>
<td>12</td>
<td>74.0</td>
</tr>
<tr>
<td>New Haven, CT, USA (51, 52)</td>
<td>12</td>
<td>69.2</td>
</tr>
<tr>
<td>NLAES, USA (53, 54)</td>
<td>12</td>
<td>74.0</td>
</tr>
<tr>
<td>Puerto Rico, USAa, c</td>
<td>12</td>
<td>70.0</td>
</tr>
<tr>
<td>Utah, USA (58)</td>
<td>Lifetime</td>
<td>74.0</td>
</tr>
<tr>
<td>Harare, Zimbabwec (59)</td>
<td>12</td>
<td>67.0</td>
</tr>
</tbody>
</table>

| Median rate untreated | 32.2 | 56.3 | 56.0 | 50.2 | 55.9 | 57.5 | 59.5 | 78.1 |
| Mean rate untreated   | 31.1 | 53.9 | 53.5 | 48.9 | 50.6 | 56.1 | 52.8 | 76.2 |

a Information in parentheses is the reference number. References for these studies can be found in Appendix 2 (web version only, available at: http://www.who.int/bulletin).
b In these studies, mood disorder was not necessarily limited to major depression.
c In these studies, substance use disorder was not necessarily limited to alcohol.

Discussion

Admittedly, the sources of data that we present are limited. Yet they seem to indicate that the treatment gap across all the psychiatric disorders examined is wide. Even for the most severe mental disorder, schizophrenia, at least one-third of individuals remain untreated.

Clearly, the rates presented here are an underestimation. There are few studies of developing countries, where services are scarce, and the studies that are available are of highly selected regions. Thus, the treatment gap for the Americas would have
been higher if all of the Latin American and Caribbean countries had been represented. As an illustration, in Belize a study of the prevalence of treatment that was based on a review of each record of all health-care providers who treated mental disorders found that about 63% of individuals with schizophrenia were untreated; 89% of those with affective disorders had not been treated; and 99% of those with an anxiety disorder also had not been treated (15). The scarcity of services in much of the world where epidemiological studies are not available is highlighted by the results of the Atlas study (12). Furthermore, common psychopharmacological agents used to treat psychosis, mania, depression and anxiety are not uniformly available (Table 3). Essential psychiatric medications at the primary care level are not available in 25% of countries (12). For 70% of the world’s population there is access to less than one psychiatrist per 100 000 people (12).

This review did not examine the extent to which the skills of traditional healers and non-professional providers are utilized. Unfortunately, only a small number of studies have examined this issue. The Chilean epidemiological survey, however, suggested that contrary to popular belief, traditional healers were rarely utilized for mental health problems (16). Evidence-based data are needed on the efficacy of treatment by traditional healers who received appropriate and adequate treatment. The primary care literature illustrates the inability of general physicians to accurately identify mental disorders and their failure to provide appropriate care (17). A study conducted in the United States among hospitalized individuals with schizophrenia revealed that over half had periods of 30 days or more off medication with an average time off medication of over seven months (18). Additionally, prevalence studies that reported on treatment utilization included individuals who are in treatment but have no current psychiatric diagnosis (19). These studies may refer to people with subclinical illness or to individuals who have benefited from treatment but no longer meet diagnostic criteria for one-year prevalence. Also, there are subclinical cases that merit treatment as they are evolving (20). If this were true, these service utilization studies might be underestimating the number of individuals with a specific diagnosis who have a post-year diagnosis and who receive treatment. Conversely, perhaps not everyone who meets diagnostic criteria needs treatment.

With regard to major depression there is some evidence that the advent of antidepressants that are better tolerated has played a part in reducing the treatment gap in countries that can afford their higher costs (21). It has also increased awareness of the disorder among primary care physicians (22). As noted in our analysis, the treatment gap was lower in the WHO European Region than in the Americas; in part this may be due to the wider availability of health coverage in western European countries. In the United States, treatment for depression increased between 1987 and 1997, despite a decline in the use of psychotherapy; this has been partially credited to expanded third-party payment for medication visits (22). This example from the United States may illustrate the role financial barriers have in contributing to the treatment gap. An alternative argument is that the increased rate of antidepressant use reflects the cohort effect of major depression and the increasing prevalence of the disorder among younger individuals (22).

Failing to reduce the treatment gap has implications beyond the impact on YLD and DALYS. An increased treatment gap has indirect economic costs. In the United States absenteeism and lost productivity at work as a result of affective disorders alone cost the nation US$ 23 billion annually and there is an additional cost of US$ 8 billion associated with premature death (23). Similarly, three-quarters of the cost of alcoholism in Germany is due to indirect factors (24). Improvements in antidepressant treatment and access to care has been credited with reducing suicide rates (25). Mental illness may result in

### Table 2. Estimates of the median treatment gap (%) by WHO region

<table>
<thead>
<tr>
<th>Mental disorder</th>
<th>Africa</th>
<th>Americas</th>
<th>Eastern Mediterranean</th>
<th>Europe</th>
<th>South-East Asia</th>
<th>Western Pacific</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schizophrenia</td>
<td>NA</td>
<td>56.8</td>
<td>NA</td>
<td>17.8</td>
<td>28.7</td>
<td>35.9</td>
</tr>
<tr>
<td>Major depression</td>
<td>67.0</td>
<td>56.9</td>
<td>70.2</td>
<td>45.4</td>
<td>NA</td>
<td>48.1</td>
</tr>
<tr>
<td>Dysthymia</td>
<td>NA</td>
<td>48.6</td>
<td>NA</td>
<td>43.9</td>
<td>NA</td>
<td>50.0</td>
</tr>
<tr>
<td>Bipolar disorder</td>
<td>NA</td>
<td>60.2</td>
<td>NA</td>
<td>39.9</td>
<td>NA</td>
<td>52.6</td>
</tr>
<tr>
<td>Panic disorder</td>
<td>NA</td>
<td>55.4</td>
<td>NA</td>
<td>47.2</td>
<td>NA</td>
<td>66.7</td>
</tr>
<tr>
<td>Generalized anxiety</td>
<td>NA</td>
<td>49.6</td>
<td>NA</td>
<td>62.3</td>
<td>NA</td>
<td>55.6</td>
</tr>
<tr>
<td>Obsessive compulsive</td>
<td>NA</td>
<td>82.0</td>
<td>NA</td>
<td>24.6</td>
<td>NA</td>
<td>62.7</td>
</tr>
<tr>
<td>Alcohol abuse/dependence</td>
<td>NA</td>
<td>72.6</td>
<td>NA</td>
<td>92.4</td>
<td>NA</td>
<td>71.6</td>
</tr>
</tbody>
</table>

* NA: Not available.

---

**Table 2.** Estimates of the median treatment gap (%) by WHO region. The scarcity of services in much of the world where epidemiological studies are not available is highlighted by the results of the Atlas study (12). Furthermore, common psychopharmacological agents used to treat psychosis, mania, depression and anxiety are not uniformly available (Table 3). Essential psychiatric medications at the primary care level are not available in 25% of countries (12). For 70% of the world’s population there is access to less than one psychiatrist per 100 000 people (12).

This review did not examine the extent to which the skills of traditional healers and non-professional providers are utilized. Unfortunately, only a small number of studies have examined this issue. The Chilean epidemiological survey, however, suggested that contrary to popular belief, traditional healers were rarely utilized for mental health problems (16). Evidence-based data are needed on the efficacy of treatment by traditional healers who received appropriate and adequate treatment. The primary care literature illustrates the inability of general physicians to accurately identify mental disorders and their failure to provide appropriate care (17). A study conducted in the United States among hospitalized individuals with schizophrenia revealed that over half had periods of 30 days or more off medication with an average time off medication of over seven months (18). Additionally, prevalence studies that reported on treatment utilization included individuals who are in treatment but have no current psychiatric diagnosis (19). These studies may refer to people with subclinical illness or to individuals who have benefited from treatment but no longer meet diagnostic criteria for one-year prevalence. Also, there are subclinical cases that merit treatment as they are evolving (20). If this were true, these service utilization studies might be underestimating the number of individuals with a specific diagnosis who have a post-year diagnosis and who receive treatment. Conversely, perhaps not everyone who meets diagnostic criteria needs treatment.

With regard to major depression there is some evidence that the advent of antidepressants that are better tolerated has played a part in reducing the treatment gap in countries that can afford their higher costs (21). It has also increased awareness of the disorder among primary care physicians (22). As noted in our analysis, the treatment gap was lower in the WHO European Region than in the Americas; in part this may be due to the wider availability of health coverage in western European countries. In the United States, treatment for depression increased between 1987 and 1997, despite a decline in the use of psychotherapy; this has been partially credited to expanded third-party payment for medication visits (22). This example from the United States may illustrate the role financial barriers have in contributing to the treatment gap. An alternative argument is that the increased rate of antidepressant use reflects the cohort effect of major depression and the increasing prevalence of the disorder among younger individuals (22).

Failing to reduce the treatment gap has implications beyond the impact on YLD and DALYS. An increased treatment gap has indirect economic costs. In the United States absenteeism and lost productivity at work as a result of affective disorders alone cost the nation US$ 23 billion annually and there is an additional cost of US$ 8 billion associated with premature death (23). Similarly, three-quarters of the cost of alcoholism in Germany is due to indirect factors (24). Improvements in antidepressant treatment and access to care has been credited with reducing suicide rates (25). Mental illness may result in...
an increased risk of living in poverty, having a lower socioeconomic status, and having lower educational attainment (26). Major depression, as well as other psychiatric disorders, has been shown to impair family function (27), increase the risk of teenage childbearing (28), and increase the risk of domestic violence (29). The impact of major depression on quality of life is as great or greater than the impact of chronic medical conditions (30). Individuals who do not seek treatment may be less clinically impaired, but there is little to suggest that treated and untreated individuals differ with regard to other psychosocial factors (31). The pervasive and chronic disablement associated with major depression disappears when individuals become asymptomatic (32). Schizophrenia, major depression, and alcohol use disorders also result in an increased risk of early mortality other than suicide (33).

One factor that may diminish concern about addressing the treatment gap in health-care planning is that at least some of these disorders, such as major depression and alcohol abuse and dependence, may remit without treatment. Randomized controlled studies suggest that more than 20% of individuals with major depression who are untreated achieve remission within 20 weeks (34). However, longitudinal studies on the course of major depression, in which treatment of identified patients was not controlled, point to a more pessimistic outcome. A WHO cross-national study of 439 patients with major depression followed for 10 years found that 36% were readmitted to hospital; 11% committed suicide; and more than 18% had a poor clinical outcome (35). A 15-year follow-up study of 380 individuals who had recovered from major depression noted that 85% had a relapse (36).

The outcome is less clear for alcohol abuse and dependence. Sustained periods of abstinence without treatment are not uncommon (37). Individuals who need treatment are more likely to have significant social impairment and psychiatric comorbidity (38); therefore, accessibility and availability of care for a sizeable proportion of individuals with alcoholism is always necessary. Naturalistic studies of panic disorder have found low probabilities of remission and high rates of relapse among those who remit (39); a similar finding was noted for OCD (40). People with schizophrenia who remain untreated are often more symptomatic; stay ill longer; and are more disabled than those who receive treatment (41).

The long-term psychosocial complications of psychiatric disorders suggest not only that the treatment gap must be bridged but also that the treatment lag (the time from onset of a disorder to obtaining care) must be shortened. Of those individuals who seek help for affective disorder and anxiety disorder, 40% do so in the year of onset. In contrast, the remaining 60% have a median delay of eight years (42). Absenteeism and poor family functioning may be present, among other consequences, when a current disorder is untreated. It has been shown for individuals with panic disorder that the longer the duration of illness prior to treatment, the poorer the social outcome (43) and the more protracted the course (39). The duration of untreated psychosis (DUP) varies widely across studies: in an Australian study the average DUP was 6 months (44), while in Nigeria it was 2.1 years for women (45). Some investigators have suggested that the longer treatment lag in schizophrenia may have a neurotoxic affect on the brain (46), although more recent research has brought this finding into question (47).

### Table 3. Availability of common psychopharmacological agents in primary care in WHO regions by country (12)

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Availability by country</th>
<th>Availability by population</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Africa</td>
<td>Americas</td>
</tr>
<tr>
<td>Diazepam</td>
<td>97.8</td>
<td>100.0</td>
</tr>
<tr>
<td>Sodium valproate</td>
<td>50.0</td>
<td>67.9</td>
</tr>
<tr>
<td>Lithium</td>
<td>36.4</td>
<td>83.3</td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>71.7</td>
<td>93.3</td>
</tr>
<tr>
<td>Chlorpromazine</td>
<td>97.8</td>
<td>92.3</td>
</tr>
<tr>
<td>Fluphenazine</td>
<td>60.9</td>
<td>64.3</td>
</tr>
<tr>
<td>Haloperidol</td>
<td>84.8</td>
<td>100.0</td>
</tr>
</tbody>
</table>

a Proportion of countries in each region where primary care physicians have access to the drug.

b Proportion of population in each region for whom primary care physicians have access to the drug.

### Box 1. Ten recommendations to address the treatment gap made in the 2001 World health report (2)

1. Mental health treatment should be accessible in primary care
2. Psychotropic drugs need to be readily available
3. Care should be shifted away from institutions and towards community facilities
4. The public should be educated about mental health
5. Families, communities and consumers should be involved in advocacy, policy-making and forming self-help groups
6. National mental health programmes should be established
7. The training of mental health professionals should be increased and improved
8. Links with other governmental and nongovernmental institutions should be increased
9. Mental health systems should be monitored using quality indicators
10. More support should be provided for research.
To address the treatment gap, the 2001 World health report (2) has laid out 10 recommendations (Box 1). WHO has created various scenarios that begin to address these recommendations taking into account the fact that resources vary widely among nations. Following the report, WHO adopted the Mental Health Global Action Programme (mhGAP), which intends to modify the current world situation (48) with the endorsement of all Member States (49). Although the treatment gap remains wide for mental disorders, appropriate policies, programmes and service developments may allow this divide to be bridged for the benefit of those in need, their families and communities.

Funding: This paper was supported by WHO.

Conflicts of interest: none declared.
The treatment gap in mental health care

Robert Kohn et al.

References


The treatment gap in mental health care


### Appendix 1

**Appendix 1. Information on prevalence studies published since 1980 that provide data on service utilization**

<table>
<thead>
<tr>
<th>Place of study (reference number)</th>
<th>Sample characteristics</th>
<th>Field dates</th>
<th>Sample size</th>
<th>Age of participants</th>
<th>Diagnostic instrument*</th>
<th>Diagnostic criteria*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia (1–3)</td>
<td>Multistage sample of Australian population</td>
<td>1997</td>
<td>10 641</td>
<td>18+</td>
<td>CIDI-A</td>
<td>ICD-10</td>
</tr>
<tr>
<td>São Paulo, Brazil (4)</td>
<td>Stratified probability sample of a middle and upper socioeconomic catchment area of the University of São Paulo Medical Center. Ages 18–24 and &gt;59 were over-sampled. Authors provided additional data used in subsequent tables.</td>
<td>1994–96</td>
<td>1 464</td>
<td>18+</td>
<td>CIDI 1.1</td>
<td>DSM-III-R</td>
</tr>
<tr>
<td>Edmonton, Canada (5, 6)</td>
<td>Multistage sample</td>
<td>1983–86</td>
<td>3 258</td>
<td>18+</td>
<td>DIS</td>
<td>DSM-III</td>
</tr>
<tr>
<td>Chile (10)</td>
<td>Multistage sample of households conducted in four catchment areas in Chile, representing each of the major geographic regions. Authors provided additional data used in subsequent tables.</td>
<td>1992–99</td>
<td>1 534</td>
<td>15+</td>
<td>CIDI 1.1</td>
<td>DSM-III-R</td>
</tr>
<tr>
<td>12 areas, China (11)</td>
<td>Twelve areas of China were surveyed with 500 urban and 500 rural families selected in each area. Psychosis and neurosis screening interviews were administered. All positives and 10% of negatives underwent the PSE.</td>
<td>NA*</td>
<td>38 136</td>
<td>15+</td>
<td>PSE</td>
<td>NPESM</td>
</tr>
<tr>
<td>14 towns, China (12)</td>
<td>Fourteen towns in one county in rural China were surveyed using a screening tool developed by Cooper et al. (1996). All positives underwent the PSE; 510 persons with schizophrenia identified.</td>
<td>NA*</td>
<td>123 572</td>
<td>15+</td>
<td>PSE</td>
<td>NPESM</td>
</tr>
<tr>
<td>Czech Republic (13, 14)</td>
<td>National probability sample</td>
<td>1999</td>
<td>2 479</td>
<td>18-79</td>
<td>CIDI 2.1</td>
<td>ICD-10</td>
</tr>
<tr>
<td>Mini survey, Finland (15, 16)</td>
<td>Random population sample of 40 areas in the country. Two phase design with the GHQ used for screening followed by a shortened PSE</td>
<td>1978–80</td>
<td>8 000</td>
<td>30+</td>
<td>GHQ/PSE</td>
<td>ICD-9</td>
</tr>
<tr>
<td>FINHCS, Finland (17, 18)</td>
<td>One-stage cluster sample. Used the UM-CIDI short form</td>
<td>1996</td>
<td>5 993</td>
<td>15–75</td>
<td>UM-CIDI</td>
<td>DSM-III-R</td>
</tr>
<tr>
<td>Munich, Germany (20)</td>
<td>Stratified sample taken from the population registry of greater Munich</td>
<td>1995</td>
<td>4 263</td>
<td>14–24</td>
<td>M-CIDI</td>
<td>DSM-IV</td>
</tr>
<tr>
<td>Madras, India (21)</td>
<td>Each head of household was screened for schizophrenia using the Indian Psychiatric Survey Schedule (IPSS). Screened positives were interviewed by a psychiatrist with the PSE</td>
<td>1985–86</td>
<td>66 281</td>
<td>15+</td>
<td>IPSS/PSE</td>
<td>ICD-9</td>
</tr>
<tr>
<td>Israel (22)</td>
<td>Ten-year birth cohort (1949–58) of Israel-born offspring of European and North African immigrants. Screening done with the Psychiatric Epidemiology Research Interview (PERI). All positives and one-fifth of negatives interviewed with SADS by psychiatrists. Authors provided additional data used in subsequent tables.</td>
<td>1988</td>
<td>2 741</td>
<td>24–33</td>
<td>PERI/SADS-I</td>
<td>RDC</td>
</tr>
<tr>
<td>Florence, Italy (23, 24)</td>
<td>Randomly selected from lists of persons registered with seven general practitioners in three districts of Florence. Study used a structured interview by physicians including questions derived from the DSM-III flow chart for affective disorders and included items from SADS-L.</td>
<td>1984</td>
<td>1 000</td>
<td>15+</td>
<td>DIS/SADS-L</td>
<td>DSM-III</td>
</tr>
</tbody>
</table>
### Place of study (reference number) | Sample characteristics | Field dates | Sample size | Age of participants | Diagnostic instrument | Diagnostic criteria
---|---|---|---|---|---|---
Beirut, Lebanon (25) | Four communities with differential exposure to acts of war were sampled: two communities within Beirut city and two communities outside the capital. Each adult member of the household was eligible to be interviewed | 1989 | 658 | 18+ | DIS | DSM-III
Mexico City, Mexico (26–28) | Multistage sample of households in 16 political divisions of Mexico City | 1995 | 1937 | 18–64 | CIDI 1.1 | DSM-III-R
Rural areas of Mexico (29) | Stratified multistage sample of 33 communities in two Mexican states | 1996–97 | 945 | 15–89 | CIDI 1.1 | ICD-10
LASA, the Netherlands (30) | Two stage interview with over-sampling of the elderly. In stage 1, 3056 participants interviewed with a screen for anxiety disorders using the CES-D and the Anxiety Subscale of the Hospital Anxiety and Depression Scale (HADS-A). | NA | 659 | 55–85 | DIS | DSM-III
NEMESIS, Netherlands (31, 32) | Multistage sample of 90 Dutch municipalities | 1998 | 7076 | 18–64 | CIDI 1.1 | DSM-III-R
Christchurch, New Zealand (33, 34) | Multistage sample of residents of Christchurch. | 1983 | 1498 | 18–64 | DIS | DSM-III
Norway (36) | Two random populations (1879 participants), in Norway given the self-administered HSCL-25. All screened positives and a proportion of negatives were given the CIDI | 1989–91 | 617 | 18+ | CIDI 1.0 | ICD-10
Zurich, Switzerland (37) | Representative sample in Zurich of 19- and 20-year-olds screened with the SCL-90 and given a diagnostic semi-structured interview (SPIKE), followed for 10 years and re-evaluated | 1989–91 | 591 | 20–30 | SPIKE | DSM-III
Taiwan, China (38, 39) | Multistage sample of metropolitan Taipei: two small towns and six rural villages | 1981–86 | 11 104 | 18+ | DIS-CM | DSM-III
Turkey (40) | Nationally representative multistage sample of households | 1993–94 | 6095 | 18–54 | CIDI 1.1 | ICD-10
ONS, United Kingdom (41) | Sample of 200 postal sectors stratified by regional health authority. Those positive on a psychosis screen were administered the SCAN | 2000 | 8800 | 16-74 | CIS-R/SCAN | ICD-10
OPCS, United Kingdom (42, 43) | Sample of 438 sectors stratified by regional health authority. Those positive on a psychosis screen were administered the SCAN and those positive for alcohol were given the AUDIT | 1993 | 10 108 | 16–64 | CIS-R/SCAN | ICD-10
Sleep Eval, United Kingdom (44) | Stratified probability sample of the United Kingdom using artificial intelligence programme in telephone interviews | 1994 | 4972 | 15+ | Sleep-Eval | DSM-IV
ECA, USA (45, 46) | Five catchment areas: New Haven, CT; Baltimore, MD; St. Louis, MO; Durham, NC; and Los Angeles, CA. In Los Angeles Hispanics were over-sampled; in St. Louis African-Americans were over-sampled; and the other three sites oversampled the elderly using multistage sampling | 1980–84 | 17 803 | 18+ | DIS | DSM-III
Mexican-Americans in CA, USA (47, 48) | Multistage sample of Fresno County, California using census tracts to select individuals of Mexican origin | 1996 | 3012 | 18–59 | CIDI 1.1 | DSM-III-R
NCS, USA (49, 50) | National, representative, stratified, multistage probability sample, with a supplemental sample of students living in campus group housing. Those with psychotic symptoms were re-interviewed with the SCID | 1990–92 | 8098 | 15–54 | UM-CIDI | DSM-III-R
## Place of study (reference number)

<table>
<thead>
<tr>
<th>Place of study (reference number)</th>
<th>Sample characteristics</th>
<th>Field dates</th>
<th>Sample size</th>
<th>Age of participants</th>
<th>Diagnostic instrument&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Diagnostic criteria&lt;sup&gt;c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Haven, CT, USA (51, 52)</td>
<td>Re-interview of an earlier household sample</td>
<td>1975–76</td>
<td>511</td>
<td>26+</td>
<td>SADS</td>
<td>RDC</td>
</tr>
<tr>
<td>NLAES, USA (53, 54)</td>
<td>National, representative, stratified, multistage probability sample, with over-sampling of participants age 28–39</td>
<td>1992</td>
<td>42 862</td>
<td>18+</td>
<td>AUDADIS</td>
<td>DSM-IV</td>
</tr>
<tr>
<td>Puerto Rico, USA (55–57)</td>
<td>Multistage sample of households in Puerto Rico. The sample does include 17 year-olds in some reports</td>
<td>1984</td>
<td>1513</td>
<td>18–64</td>
<td>DIS</td>
<td>DSM-III</td>
</tr>
<tr>
<td>Utah, USA (58)</td>
<td>Sample selected from Medicare records in Cache County</td>
<td>1995–96</td>
<td>4559</td>
<td>65+</td>
<td>DIS</td>
<td>DSM-IV</td>
</tr>
<tr>
<td>Harare, Zimbabwe (59)</td>
<td>Randomly selected women were screened using the Shona Screen for Mental Disorders. Those above the cut-off were given the PSE. Depression was diagnosed based on Bedford College Criteria. Only women included in the study</td>
<td>1991–92</td>
<td>172</td>
<td>18–65</td>
<td>PSE</td>
<td>Bedford</td>
</tr>
</tbody>
</table>

* Not applicable.

<sup>b</sup> Diagnostic interview schedules included: AUDADIS, Alcohol Use Disorder and Associated Disabilities Interview Schedule; AUDIT, Alcohol-Use Identification Test; CES-D, Center for Epidemiological Study Depression scale; CIDI, Composite International Diagnostic Interview; CIS-R, Revised Clinical Interview Schedule; DIS, Diagnostic Interview Schedule; GHQ, General Health Questionnaire; HADS-A, Anxiety Subscale of the Hospital Anxiety and Depression Scale; HSCL, Hopkins Symptom Checklist; IPSS, Indian Psychiatric Survey Schedule; M-CIDI, Munich CIDI; PERI, Psychiatric Epidemiology Research Interview; PSE, Present State Examination; SADS, Schedule of Affective Disorders and Schizophrenia; SADS-I, SADS Israel; SADS-L, SADS lifetime; SCAN, Schedule for the Clinical Assessment of Neuropsychiatry; UM-CIDI, University of Michigan CIDI; SCL, Symptom Checklist; SPIKE, Structured Psychopathological Interview and Rating of the Social Consequences for Epidemiology.

<sup>c</sup> Diagnostic criteria included: DSM, Diagnostic and Statistical Manual of Mental Disorders; ICD, International Classification of Diseases; CCMD, Chinese Classification and Diagnostic Criteria of Mental Disorder; RDC, Research Diagnostic Criteria.
Appendix 2

References for prevalence studies published since 1980 that provide data on service utilization


Robert Kohn et al.


